BioSpace News Archive

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at the UBS Virtual Global Healthcare Conference on Wednesday, May 20, 2020, at 8:20 AM EDT.

iSpecimen today announced it will supply the U.S. Centers for Disease Control and Prevention (CDC) with serum samples from subjects who have previously tested positive for SARS-CoV-2, the virus that causes COVID-19.

The designation reflects AIS Healthcare’s commitment to advancing quality throughout the care continuum.

Timber Pharmaceuticals LLC (“Timber”), a privately held biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today announced its support for Ichthyosis Awareness Month.

Bolt Biotherapeutics, Inc., a private clinical-stage biotechnology company developing Immune-Stimulating Antibody Conjugates (ISACs) to harness the power of the immune system to treat cancer, today announced the appointment of William P. Quinn as chief financial officer.

Company Secures EU Certification for First-of-its-Kind Continuous Monitoring System Capable of Assessing and Trending Glucose, Lactate and Scv02 in Single Micro-Sample of Blood [12-May-2020] HAYWARD, Calif. , May 12, 2020 /PRNewswire/ -- OptiScan Biomedical Corporation, developer of the only automated, multi-analyte, bedside, continuous blood monitoring system for use

YUMAB, a German antibody development company, announced today it has identified fully human monoclonal antibodies with neutralizing activity against patient-derived coronavirus strain SARS-CoV2.

83 million Germans, covered for work and commuting-related accidents, have the opportunity to access ReWalk products if the requirements and personal suitability are met

Tyme Technologies, Inc. (NASDAQ:TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that the Company will host a conference call and live webcast on Wednesday, May 20, 2020 at 5:00 P.M. ET to report its financial and operating results for its fourth quarter and fiscal year ended March 31, 2020. TYME delivered on multiple major milestones in Fiscal Year 2020, including the h

Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio, will present a company overview at the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 2:10 p.m. ET. The presentation will include additional details on